Your browser doesn't support javascript.
loading
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.
Yeboah, Muchaala; Papagregoriou, Charys; Jones, Des C; Chan, H T Claude; Hu, Guangan; McPartlan, Justine S; Schiött, Torbjörn; Mattson, Ulrika; Mockridge, C Ian; Tornberg, Ulla-Carin; Hambe, Björn; Ljungars, Anne; Mattsson, Mikael; Tews, Ivo; Glennie, Martin J; Thirdborough, Stephen M; Trowsdale, John; Frendeus, Björn; Chen, Jianzhu; Cragg, Mark S; Roghanian, Ali.
  • Yeboah M; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
  • Papagregoriou C; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
  • Jones DC; Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
  • Chan HTC; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
  • Hu G; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • McPartlan JS; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Schiött T; BioInvent International AB, Lund, Sweden.
  • Mattson U; BioInvent International AB, Lund, Sweden.
  • Mockridge CI; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
  • Tornberg UC; BioInvent International AB, Lund, Sweden.
  • Hambe B; BioInvent International AB, Lund, Sweden.
  • Ljungars A; BioInvent International AB, Lund, Sweden.
  • Mattsson M; BioInvent International AB, Lund, Sweden.
  • Tews I; Institute for Life Sciences and.
  • Glennie MJ; Biological Sciences, University of Southampton, Southampton, United Kingdom.
  • Thirdborough SM; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
  • Trowsdale J; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
  • Frendeus B; Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
  • Chen J; BioInvent International AB, Lund, Sweden.
  • Cragg MS; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Roghanian A; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
JCI Insight ; 5(18)2020 09 01.
Article en En | MEDLINE | ID: mdl-32870822
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Monocitos / Receptores Inmunológicos / Antígenos CD / Proteínas de Punto de Control Inmunitario / Tolerancia Inmunológica / Linfoma / Epítopos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Monocitos / Receptores Inmunológicos / Antígenos CD / Proteínas de Punto de Control Inmunitario / Tolerancia Inmunológica / Linfoma / Epítopos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2020 Tipo del documento: Article